In this presentation from “Lymphoma and Myeloma 2015: An International Congress on Hematologic Malignancies”, Dr. Allison Moskowitz argues that single-agent brentuximab is the best second-line approach to induce lymphoma remission prior to stem cell transplant (SCT).
A continuing education program is offered as a supplement to this webcast at the following location:
http://elc.imedex.com/ELC/Activity-Search.aspx?search=LM2015EP
© 2015 Imedex, LLC.